Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Alzheimer's Disease Research - Completed Award

Photo Pending

Guojun Bu, Ph.D.

Washington University
St. Louis, MO

Title: Modulation of APP Trafficking and Abeta Production
Non-Technical Title:

Duration: April 1, 2006 - March 31, 2008
Award Type: Standard
Award Amount: $300,000

Details:

Amyloid β-peptide (Aβ) accumulation in the brain is a pathological hallmark of Alzheimer’s disease (AD). Recent studies have shown that aggregated forms of Aβ is toxic to neurons and contribute to memory loss in AD. The toxic Aβ is derived from sequential cleavage of a larger protein called the amyloid precursor protein, or APP. Increased APP cleavage can directly cause AD. APP is a dynamic molecule that moves among different compartments within cells. The general hypothesis is that APP cycling between cell surface and inside the cells increases its chance to be cleaved to Aβ. Dr. Bu has identified three important molecules called LRP, LRP1B, and sorting nexin 17 (SNX17), each interacts with APP and modifies its cycling speed. Specifically, the preliminary studies found that LRP and SNX17 facilitate and LRP1B inhibits APP cycling. The goal of this proposal is to analyze in brain-derived neurons whether their effects on APP cycling also translate into changes in Aβ production. If the results are confirmed, drugs can be designed to increase LRP1B levels or decrease LRP and SNX17 levels to benefit AD patients.